

FREE NATALIZUMAB INTERFERENCE OF THE IMMUNOASSAY FOR ANTI-NATALIZUMAB ANTIBODIES
20 ug/mL 12C4
0.1 ug/mL 12C4
2.82 ug/mL; POOLED PATIENT SERA
O.D.
Ab:FREE DRUG AT CUT-OFF~0.5
Ab:FREE DRUG AT CUT-OFF~2.5
Ab:FREE DRUG AT CUT-OFF~2
NEGATIVE CUT-OFF
FREE NATALIZUMAB (ug/mL)

Fig. 1



FREE NATALIZUMAB INTERFERENCE OF THE BLOCKING ASSAY FOR ANTI-NATALIZUMAB ANTIBODIES
MFI
500
400
300
200
100
0
MFImax
NEGATIVE CUT-OFF
~6.4
~0.12
Ab:FREE NATALIZUMAB
BIOTIN-NATALIZUMAB = 0.3 ug/mL
12C4 = 0.064 ug/mL
0.001
0.01
0.1
1
10
FREE NATALIZUMAB (µg/mL)

Fig. 2



PROBABILITY OF AN ANTIBODY POSITIVE RESULT
1.0
0.8
0.6
0.4
0.2
0.0
0
12
24
36
WEEKS
NUMBER OF SUBJECTS AT RISK
56
18
1
0

Fig. 3



EFFECT OF ANTIBODIES ON RELAPSE RATE
UNADJUSTED RELAPSE RATE (±SE)
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.70
0.22
0.28
0.46
P
AN
TP
PP

Fig. 4



EFFECT OF ANTIBODIES ON RELAPSE RATE
0-3 MONTHS
UNADJUSTED RELAPSE RATE (±SE)
1.0
0.8
0.6
0.4
0.2
0.0
0.71
0.30
0.43
0.34
P
AN
TP
PP

Fig. 5A



EFFECT OF ANTIBODIES ON RELAPSE RATE
3-6 MONTHS
UNADJUSTED RELAPSE RATE (±SE)
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.64
0.21
0.45
0.75
P
AN
TP
PP

Fig. 5B



EFFECT OF ANTIBODIES ON RELAPSE RATE
6-9 MONTHS
UNADJUSTED RELAPSE RATE (±SE)
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.69
0.20
0.23
0.69
P
AN
TP
PP

Fig. 5C



EFFECT OF ANTIBODIES ON RELAPSE RATE
9-12 MONTHS
UNADJUSTED RELAPSE RATE (±SE)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.66
0.21
0.00
0.45
P
AN
TP
PP

Fig. 5D